Lite Strategy (LITS) Accumulated Expenses (2011 - 2026)
Lite Strategy (LITS) posted quarterly Accumulated Expenses of $699000.0 for Q1 2026, down 34.12% year-over-year from $1.1 million in Q1 2025, and down 8.03% quarter-over-quarter from $760000.0 in Q4 2025.
Lite Strategy (LITS) Accumulated Expenses (2011 - 2026) Analysis & Trends
Lite Strategy's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $699000.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 34.12% year-over-year to $699000.0; the TTM figure through Mar 2026 stood at $699000.0 (down 34.12% YoY), while the FY2025 annual figure was $873000.0, down 69.05% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $699000.0, down from $760000.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $16.3 million in Q1 2023, with the low at $260000.0 in Q3 2025.
- The 5-year median for Accumulated Expenses is $4.3 million (2023), against an average of $5.1 million.
- The sharpest annual moves came in 2023 and 2025: Accumulated Expenses surged 65.42% in 2023, then plunged 86.29% in 2025.
- Lite Strategy's Accumulated Expenses stood at $14.3 million in 2022, then plunged by 60.65% to $5.6 million in 2023, then tumbled by 73.85% to $1.5 million in 2024, then sank by 48.51% to $760000.0 in 2025, then declined by 8.03% to $699000.0 in 2026.
- Business Quant data shows LITS's Accumulated Expenses at $699000.0 in Q1 2026, $760000.0 in Q4 2025, and $260000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 699,000.00 |
| Dec 31, 2025 | 760,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 873,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 5.39 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 4.29 Mn |
| Jun 30, 2023 | 7.19 Mn |
| Mar 31, 2023 | 16.26 Mn |
| Dec 31, 2022 | 14.35 Mn |
| Sep 30, 2022 | 9.22 Mn |
| Jun 30, 2022 | 4.35 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 9.77 Mn |
| Sep 30, 2021 | 6.10 Mn |
| Jun 30, 2021 | 3.51 Mn |